comprehensive -WSS

comprehensive

author：explore 2025-09-07 14:06:47 - browse：83466

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： CDC launches VaccineFinder tool to locate Covid

focus

WSS

Bird flu surveillance in wastewater gets boost from consortium

Biden praises World Series champion Astros for impact off the field during White House celebration

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Study finds gene variants tied to breast cancer risk in Black women

Liver decline slowed by off

Making the case for fair compensation in clinical trials

leisure time

comprehensive

entertainment

How one medical school became remarkably diverse

More regulation could be coming for drug ads

Affirmative action in medical school literally saved lives

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Trump demands the U.S. pay no more for drugs than other countries … again

Liver decline slowed by off

Alkermes shareholders re

Discs beat pads, tampons for heavy menstrual flow, new study shows

DIEP, the 'gold standard' of breast reconstruction, is under threat

Astronauts get first look at the spacecraft that will fly them around the moon

hotspot

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

Hospitals use virtual reality to design more inclusive rooms for kids

‘The Bear’ and hospitality in hospitals

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Eyeing GLP

Lessons Learned: This is why you network to find that industry job you want

leisure time

focus

focus

hotspot